Resectable NSCLC

SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

All
FEATURED
ILCS
Webinars
Articles

       Industry Sponsored

Featured Sessions

Prof. Martin Reck
Nov 04 2026
SPONSORED INTERVIEW
Resectable NSCLCImmunotherapies

MDT-BRIDGE in Resectable and Borderline Resectable NSCLC

Prof. Martin Reck presents and discusses the phase 2 MDT-BRIDGE trial in resectable and borderline resectable non-small cell lung cancer in this on-demand expert talk.

M. Reck

       From Our Annual Summit

ILCS Sessions

Patient Cases
Oct 04 2024
ILCS 2024
Advanced NSCLCResectable NSCLC

Patient Cases & Open Questions

} 32 min
Nuria Maria Novoa
Oct 04 2024
ILCS 2024
Resectable NSCLC

Surgical Dilemmas: Defining Resectability for Optimal Patient Outcomes in the IO Era

} 27 min

N. Novoa

       Expert Insights

Webinars

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

       The Reading Room

Articles & Research

Nikolaj Frost
Oct 31 2026
RESEARCH
Resectable NSCLCImmunotherapies

KEYNOTE-867 tested pembrolizumab with SBRT in unresected stage I or II NSCLC

N. Frost
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies

Early ctDNA clearance was associated with longer event-free survival in resectable NSCLC in NeoCOAST-2

T. CasconeP. Forde
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 15 2026
NEWS
Resectable NSCLC

A papal diagnosis turns the world’s attention to its most diagnosed cancer

Oct 14 2026
RESEARCH
Resectable NSCLC

More lymph nodes examined at segmentectomy tracked with longer survival in early-stage NSCLC

J. Perentes
Oct 03 2026
RESEARCH
Advanced NSCLCResectable NSCLCTargeted Therapies

AI-extracted records describe stage I–III NSCLC care at four Spanish hospitals before immunotherapy

A. Calles
Sep 30 2026
RESEARCH
Resectable NSCLC

Spread through air spaces predicted relapse after both lobectomy and segmentectomy in JCOG0802 stage IA NSCLC

S. BerezowskaL. BubendorfP. Hofman
Martin Reck
Sep 28 2026
RESEARCH
Resectable NSCLCImmunotherapies

AEGEAN’s second interim analysis kept the EFS benefit of perioperative durvalumab, on an OS reading that crosses 1

M. ReckM. Hochmair
Sep 25 2026
RESEARCH
Resectable NSCLCTargeted Therapies

Multi-omic profiling separated recurrence risk within pathological stage in resected EGFR-mutant lung adenocarcinoma

S. Saw
Sep 19 2026
RESEARCH
Resectable NSCLC

Spread through air spaces carried an HR of 2.32 for DFS in stage 1 lung adenocarcinoma

S. Saw
Sep 17 2026
CONGRESS
Resectable NSCLCTargeted Therapies

Adjuvant osimertinib reduced the risk of death by 47% at eight years in ADAURA

Sep 15 2026
CONGRESS
Advanced NSCLCBiomarkersResectable NSCLC

WCLC 2026, day 4: tumour budding, BRAF class II and III, brain radiotherapy timing, and mobile CT screening

Sep 14 2026
CONGRESS
Resectable NSCLCTargeted Therapies

ADAURA at eight years: adjuvant osimertinib keeps a 15-point overall survival lead

Sep 14 2026
CONGRESS
Advanced NSCLCResectable NSCLCADCs

WCLC 2026, day 3: EGFR exon 20, ROS1 and HER2 in advanced NSCLC, and 79% alive at eight years after surgery

Sep 12 2026
CONGRESS
Advanced NSCLCResectable NSCLCSCLC

WCLC 2026, day 1: extended-interval and subcutaneous dosing in SCLC, and a 70% early response

Aug 31 2026
RESEARCH
Resectable NSCLCTargeted Therapies

Adjuvant alectinib held its advantage in ALINA’s Asia subgroup, on 31 events and immature survival data

H. Horinouchi
Aug 25 2026
RESEARCH
Resectable NSCLCTargeted Therapies

ALINA: fewer patients stopped adjuvant alectinib than chemotherapy; quality-of-life gains held to two years

M. HochmairH. HorinouchiD. Planchard
Antonio Passaro
Aug 19 2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies

AIOT expert panel endorses chemo-immunotherapy as a new standard in resectable stage II-III NSCLC

T. CasconeP. FordeA. Passaro

       Industry Sponsored

Featured Sessions

Prof. Martin Reck
Nov 04 2026
SPONSORED INTERVIEW
Resectable NSCLCImmunotherapies

MDT-BRIDGE in Resectable and Borderline Resectable NSCLC

Prof. Martin Reck presents and discusses the phase 2 MDT-BRIDGE trial in resectable and borderline resectable non-small cell lung cancer in this on-demand expert talk.

M. Reck

       From Our Annual Summit

ILCS Sessions

Patient Cases
Oct 04 2024
ILCS 2024
Advanced NSCLCResectable NSCLC

Patient Cases & Open Questions

} 32 min
Nuria Maria Novoa
Oct 04 2024
ILCS 2024
Resectable NSCLC

Surgical Dilemmas: Defining Resectability for Optimal Patient Outcomes in the IO Era

} 27 min

N. Novoa

       Expert Insights

Webinars

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

       The Reading Room

Articles & Research

Nikolaj Frost
Oct 31 2026
RESEARCH
Resectable NSCLCImmunotherapies

KEYNOTE-867 tested pembrolizumab with SBRT in unresected stage I or II NSCLC

N. Frost
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies

Early ctDNA clearance was associated with longer event-free survival in resectable NSCLC in NeoCOAST-2

T. CasconeP. Forde
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 15 2026
NEWS
Resectable NSCLC

A papal diagnosis turns the world’s attention to its most diagnosed cancer

Oct 14 2026
RESEARCH
Resectable NSCLC

More lymph nodes examined at segmentectomy tracked with longer survival in early-stage NSCLC

J. Perentes
Oct 03 2026
RESEARCH
Advanced NSCLCResectable NSCLCTargeted Therapies

AI-extracted records describe stage I–III NSCLC care at four Spanish hospitals before immunotherapy

A. Calles
Sep 30 2026
RESEARCH
Resectable NSCLC

Spread through air spaces predicted relapse after both lobectomy and segmentectomy in JCOG0802 stage IA NSCLC

S. BerezowskaL. BubendorfP. Hofman
Martin Reck
Sep 28 2026
RESEARCH
Resectable NSCLCImmunotherapies

AEGEAN’s second interim analysis kept the EFS benefit of perioperative durvalumab, on an OS reading that crosses 1

M. ReckM. Hochmair
Sep 25 2026
RESEARCH
Resectable NSCLCTargeted Therapies

Multi-omic profiling separated recurrence risk within pathological stage in resected EGFR-mutant lung adenocarcinoma

S. Saw
Sep 19 2026
RESEARCH
Resectable NSCLC

Spread through air spaces carried an HR of 2.32 for DFS in stage 1 lung adenocarcinoma

S. Saw
Sep 17 2026
CONGRESS
Resectable NSCLCTargeted Therapies

Adjuvant osimertinib reduced the risk of death by 47% at eight years in ADAURA

Sep 15 2026
CONGRESS
Advanced NSCLCBiomarkersResectable NSCLC

WCLC 2026, day 4: tumour budding, BRAF class II and III, brain radiotherapy timing, and mobile CT screening

Sep 14 2026
CONGRESS
Resectable NSCLCTargeted Therapies

ADAURA at eight years: adjuvant osimertinib keeps a 15-point overall survival lead

Sep 14 2026
CONGRESS
Advanced NSCLCResectable NSCLCADCs

WCLC 2026, day 3: EGFR exon 20, ROS1 and HER2 in advanced NSCLC, and 79% alive at eight years after surgery

Sep 12 2026
CONGRESS
Advanced NSCLCResectable NSCLCSCLC

WCLC 2026, day 1: extended-interval and subcutaneous dosing in SCLC, and a 70% early response

Aug 31 2026
RESEARCH
Resectable NSCLCTargeted Therapies

Adjuvant alectinib held its advantage in ALINA’s Asia subgroup, on 31 events and immature survival data

H. Horinouchi
Aug 25 2026
RESEARCH
Resectable NSCLCTargeted Therapies

ALINA: fewer patients stopped adjuvant alectinib than chemotherapy; quality-of-life gains held to two years

M. HochmairH. HorinouchiD. Planchard
Antonio Passaro
Aug 19 2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies

AIOT expert panel endorses chemo-immunotherapy as a new standard in resectable stage II-III NSCLC

T. CasconeP. FordeA. Passaro
Aug 13 2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies

Pre-surgical ctDNA clearance reached 66% with neoadjuvant nivolumab against 38% with placebo in CheckMate 77T

T. Cascone
Aug 06 2026
RESEARCH
Resectable NSCLCTargeted Therapies

Adjuvant crizotinib did not prolong DFS in resected ALK-positive NSCLC

J. SandsP. Forde
Aug 02 2026
RESEARCH
Resectable NSCLCImmunotherapies

Five-year event-free survival was 49.9% with perioperative pembrolizumab against 26.5% in KEYNOTE-671

D. Rodríguez-AbreuM. Reck